Why Shares of Aratana Therapeutics Fell Off a Cliff in September

By Brian Feroldi – Oct 25, 2015 at 4:16PM

NASDAQ: PETX

Aratana Therapeutics

Shares of the pet medicine maker fall hard on the heels of lackluster clinical trial results.

Shares of Aratana Therapeutics (PETX), a small-cap company focused on animal health, dropped more than 50% in September after the company released disappointing clinical trial results.

Is this drop a buying opportunity? See the presentation below for details.

The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.